搜索结果


   SOD2

靶点ID:TCMBANKGE001076


靶点别名:GClnc1; IPO-B; IPOB; MNSOD; MVCD6; Mn-SOD


靶点描述:superoxide dismutase 2


染色体:6


染色体位置:6q25.3


靶点类型:protein-coding


HERB_ID:HBTAR003850


HGNC_Link:11180


OMIM_Link:147460


Ensembl_Link:ENSG00000112096; ENSG00000285441


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000003 rotenone rotenone C23H22O6 394.4 g/mol CC(=C)C1CC2=C(O1)C=CC3=C2OC4COC5=CC(=C(C=C5C4C3=O)OC)OC
TCMBANKIN000052 cannabidiol abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 C21H30O2 314.5 g/mol CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O
TCMBANKIN000065 dioscin LMST01080053; C08897; 3-O-(Rhaa1-4(Rhaa1-2)Glcb)-(25R)-spirost-5-en-3beta-ol; dioscin ; 19057-60-4; Dioscin C45H72O16 869.04 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1
TCMBANKIN000113 vinblastine vinblastine C46H58N4O9 810.97 CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
TCMBANKIN014187 seo-wenyujinacid B C2H6OS or HSCH2CH2OH C(CS)O
TCMBANKIN019942 vitamin e vitamin-e; LS-187838; alpha-tocopherol; tocopherol; β-Tocopherol; α-tocopher C29H50O2 430.7 g/mol CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C
TCMBANKIN027842 vincristine AC-20336; 57-22-7; AKOS015965501 C46H56N4O10 825 g/mol CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
TCMBANKIN028288 morphine (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol; 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol; RMS; Hard stuff; Morpho; Cube juice; 47106-99-0; EINECS 200-320-2; 64-31-3 (SULFATE); (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol; (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Morphin; Nepenthe; Roxanol; (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL; CCRIS 5762; AIDS-001987; Moscontin; Statex SR; Unkie; Morphia; Morphina [Italian]; M-Eslon; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-, (5alpha,6alpha)-; Morphinum; Ms Emma; 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol; (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol; Dolcontin; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4a,5,7a,8-tetrahydro-12-methyl-; Morphinism; Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5..alpha.,6.alpha.)-; MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE; 57-27-2 (FREE BASE ); (-)-Morphine; Dulcontin; 8053-16-5; Meconium; (-)Morphine sulfate; Ospalivina; NSC11441(SULFATE); Morphium; Morphin [German]; l-Morphine; 9H-9,9c-Iminoethanophenanthro(4,5-bcd)furan-3,5-diol, 4alpha,5,7alpha,8-tetrahydro-12-methyl-; Dreamer; HSDB 2134; Hocus; 85201-37-2; AIDS001987; 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol; DEA No. 9300; Duromorph; Morfina [Italian]; Morphina; Morphinan-3,6-alpha-diol, 7,8-didehydro-4,5-alpha-epoxy-17-methyl-; MOI; CHEBI:17303 C17H19NO3 285.34 CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
TCMBANKIN029987 Daturameteloside I 636.86
TCMBANKIN036904 isovitexin beta-D-isovitexin; LMPK12110338; Iso Vitexin; CHEBI:18330; 61383-34-4; C01714; 61838-34-4; 29702-25-8; 6-beta-D-Glucopyranosyl-4',5,7-trihydroxyflavone; 4H-1-Benzopyran-4-one, 6-beta-D-glucopyranosyl-5,7- dihydroxy-2-(4-hydroxyphenyl)-; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-4-chromenone; 6-Glucosylapigenin; Isovitexin; Apigenin-6-C-glucoside; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]chromone; Apigenin 6-C-glucoside; 38953-85-4; NCGC00163578-01; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; Saponaretin; 4H-1-Benzopyran-4-one, 6-beta-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)- (VAN); AIDS339232; (1S)-1,5-anhydro-1-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-6-yl]-D-glucitol; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; 6-C-Glucosylapigenin; AIDS-339232 C20H18O10 418.351 c1(C2=C([H])C(=O)c(c(O[H])c([C@@]3([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(O[H])O3)c(O[H])c4[H])c4O2)c([H])c([H])c(O[H])c([H])c1[H]
TCMBANKIN036916 Artemisinin BSPBio_002998; KBio2_001831; BRN 4194670; Prestwick1_000498; LMPR01030025; Spectrum_001351; Artemisia annua L., extract; (3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; KBio2_004399; KBioSS_001831; KBio2_006967; Spectrum2_001512; Huanghuahaosu; Qinghaosu; Qing Hao Su; SPBio_001583; Artemisinine [French]; Artemisininum [Latin]; Arteannuin; (+)-Artemisinin; Artemisinina [Spanish]; artemisinin ; BPBio1_000435; Cotexin; KBio1_000656; Prestwick3_000498; KBioGR_000982; Qinghosu; Qinghaosu [Chinese]; Artesin; Quing Hau Sau; Prestwick2_000498; Spectrum5_001098; IDI1_000656; C09538; DivK1c_000656; Artemisinin [INN]; Artemisine; Qing Hau SU; 3,12-Epoxy-12H-pyranol(4,3-j)-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR*)-(+)-; BSPBio_000395; Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one; NSC 369397; Spectrum3_001549; KBio3_002498; 63968-64-9; NINDS_000656; SPBio_002316; Spectrum4_000721; D02481; Artemisinin; Artemisinine; Prestwick0_000498; Qing Hau Sau [Chinese] C15H22O5 282.332 C1([H])([H])[C@]2([H])[C@]3([C@@]([H])(O[C@@](C([H])([H])[H])(OO3)C([H])([H])C4([H])[H])OC(=O)[C@]2([H])C([H])([H])[H])[C@]4([H])[C@]([H])(C([H])([H])[H])C1([H])[H]
TCMBANKIN037813 genistein BSPBio_002375; Lopac-G-6649; NCGC00015479-02; K00046; Genisteol; Spectrum_000320; NCGC00025005-01; Sophoricol; KBio2_003368; 4,6,7-Trihydroxyisoflavone; SMR000112580; SIPI 807-1; KBio2_007700; 5,7,4'-Trihydroxyisoflavone; Spectrum4_001543; GEN; NCGC00025005-04; Lopac0_000520; AIDS097204; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; Spectrum5_000106; Bio1_001423; NCGC00025005-05; NSC 36586; NCGC00025005-02; 4′,5,7-Trihydroxyisoflavone; Differenol A; NPI 031L; ACon1_001065; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-; Bio1_000934; NCI60_003369; UPCMLD-DP096:001; NCGC00015479-01; genistein ; Spectrum2_000638; KBio2_002564; nchembio.76-comp6; G6776_SIGMA; DivK1c_006401; 5-18-04-00594 (Beilstein Handbook Reference); cMAP_000086; EU-0100520; 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate; Tocris-1110; CHEBI:74224; KBioGR_002006; Bio1_000445; BRN 0263823; 446-72-0; MEGxp0_000568; Oprea1_437815; SMP1_000133; KBio1_001345; 5,7-DIHYDROXY-3-(4-HYDROXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; Lactoferrin-genistein; SPECTRUM210296; 4',5, 7-trihydroxyisoflavone; NSC36586; EINECS 207-174-9; CHEBI:28088; Oprea1_224620; AIDS-097204; 4',5,7-Trihydroxyisoflavone; C06563; KBio3_003042; SPBio_000636; genistein(1-); KBio2_000800; 4′,5,7-Trihydroxyisoflavone; G6649_SIGMA; Prunetol; KBioGR_002564; C.I. 75610; KBioSS_000800; Genistein; TNP00151; CCRIS 7675; MolMap_000022; KBio2_005132; KBio3_001595; ZINC00041692; AIDS016499; ST056352; SpecPlus_000305; Isoflavone, 4',5,7-trihydroxy-; 4',5,7-Trihydroxy isoflavone; STO514; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one; KBioSS_002573; KBio2_005936; Genistein; 4',5,7-Trihydroxyisoflavone; Spectrum3_000678; PTI G4660; AIDS-016499; nchembio.2007.28-comp32; Genisterin; NCGC00025005-07; MLS000738127 C15H10O5 270.24 C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
TCMBANKIN049920 alpha-Lipoic acid α-lipoicacid; 5-[1,2]-dithiolan-3-yl-pentanoic acid C8H14O2S2 206.326 C1([H])([H])C([H])([H])[C@]([H])(SS1)C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(=O)O[H]
TCMBANKIN050200 Zincpolyanemine 317.7 g/mol
TCMBANKIN057899 arsenicum;arsenic;as As 74.92159 g/mol [As]
TCMBANKIN057905 ferrum iron Fe 55.84 g/mol [Fe]
TCMBANKIN057911 se selenium H2Se 78.97 g/mol [Se]
TCMBANKIN057942 Dehydroascorbate dehydroascorbic acid C6H6O6 174.11 g/mol C(C(C1C(=O)C(=O)C(=O)O1)O)O
TCMBANKIN057960 glutathion glutathione C10H17N3O6S 307.33 g/mol C(CC(=O)NC(CS)C(=O)NCC(=O)O)C(C(=O)O)N
TCMBANKIN058205 trans-resveratrol (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene C14H12O3 228.24 g/mol C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN058206 resveratrol- 3-O-β-D-glucoside Resveratrol-3- O-B-D- glucopyranoside C20H22O8 C1=CC(=CC=C1C=CC2=CC(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O
TCMBANKIN058416 chrysazin LTAN;danthron;9,10-Anthracenedione, 1,8-dihydroxy-; KBioGR_001944; ACon1_000135; Spectrum4_001682; NCI60_041443; 1,8-Dihydroxy-9,10-anthracenedione; 1,8-dihydroxyanthra-9,10-quinone; 1,8-Dihydroxyanthrachinon [Czech]; KBio2_002230; Roydan; Istan; InChI=1/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16; Chrysazin; Spectrum_001750; Modane; Usaf nd-59; Dantron; NSC 38626; AIDS-001375; EU-0099935; Danivac; EINECS 204-173-5; 1,8-Dihydroxy-9,10-anthraquinone; 117-10-2; Dionone; Laxanorm; CCRIS 3529; Dioxyanthrachinonum; KBio2_007366; Dorbanex; AI3-38117; NCGC00091367-02; NSC646568; Altan; NCGC00091367-01; Anthraquinone, 1,8-dihydroxy-; 1,8-Dihydroxyanthracene-9,10-dione; Laxanthreen; KBioSS_002230; MEGxp0_001693; NSC 646568; 1,8-Dihydroxyanthraquinone; C10312; component of Modane; Danthron [BAN]; D108103_ALDRICH; Laxipur; Duolax; CHEBI:3682; BSPBio_002259; ZINC03860369; ST5330603; AIDS001375; Dantrona [INN-Spanish]; Dorbane; KBio3_001479; Zwitsalax; NSC7210; SPECTRUM211468; Scatron D; SMR000059018; Spectrum5_000324; Chrysazine; NSC38626; Danthron; Spectrum3_000650; Pastomin; Dantrone [INN-French]; KBio1_000284; MLS000069608; 1,8-Dihydroxyanthrachinon; component of Doxidan; IDI1_000284; Laxipurin; Antrapurol; DivK1c_000284; Diaquone; Bancon; Neokutin S; Dantronum [INN-Latin]; NCIMech_000114; Spectrum2_000603; 343235-40-5; Istizin; 32073-07-7; component of Doxan; SPBio_000506; KBio2_004798; component of Dorbantyl; 1,8-Dihydroanthraquinone; NINDS_000284; WLN: L C666 BV IVJ DQ NQ; 1,4,5,8-Tetroxyantraquinone; Prugol;danthron; Chrysazine; Danthron; CAS-117-10-2; Z4XE6IBF3V; NCGC00091367-05; 9,10-Anthracenedione, 1,8-dihydroxy-; KBioGR_001944; ACon1_000135; 3nsq; Spectrum4_001682; NCI60_041443; 1,8-Dihydroxy-9,10-anthracenedione; 1,8-bis(oxidanyl)anthracene-9,10-dione; Danthron [USP]; 1,8-Dihydroxyanthrachinon [Czech]; KBio2_002230; Roydan; DSSTox_CID_328; Istan; BBL013161; InChI=1/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16; dihydroxyanthraquino ne; 1,8-Dihydroxyanthraquinone, Vetec(TM) reagent grade, 96%; Chrysazin; Spectrum_001750; Modane; Usaf nd-59; HMS2091A09; Dantron; NSC 38626; 9, 1,8-dihydroxy-; Dantron, INN; NSC755828; SBI-0051330.P003; EU-0099935; Dantron [INN]; CCG-35470; DB04816; Danivac; HMS3715F08; D0J0EL; ST50330603; NCGC00091367-06; UNII-Z4XE6IBF3V; EINECS 204-173-5; Dantron (Chrysazin; 8,9-DIHYDROXYANTHRACENE-1,10-DIONE; 1,8-Dihydroxy-9,10-anthraquinone; danthro-lax; HSDB 7764; Dionone; 117-10-2; Laxanorm; CCRIS 3529; NSC-646568; Criasazin; Dioxyanthrachinonum; KBio2_007366; RTR-003068; Dorbanex; ANW-17004; SBB057973; AI3-38117; NCGC00258539-01; dianthon; Danthron (1,8-Dihydroxyanthracene-9,10-dione); STK238373; HMS500O06; 8,9-dihydroxy-1,10-anthraquinone; NSC646568; ZX-AT013456; NCGC00091367-02; Altan; 1,8-dioxyanthraquinone; NCGC00091367-01; Anthraquinone, 1,8-dihydroxy-; Laxanthreen; 1,8-Dihydroxyanthracene-9,10-dione; SR-01000721864-2; AB1006759; I14-16739; KBioSS_002230; 1,8-Dihydroxyanthra-9,10-quinone #; MEGxp0_001693; KS-00000W95; NSC 646568; 1,8-Dihydroxyanthraquinone; MolPort-000-564-798; C10312; AC1L1EU5; component of Modane; Danthron [BAN]; Laxipur; Duolax; DTXSID9020328; Laxapur; LTAN; 1,8-Dihydroxy-9,10-anthracenedione, 9CI; MFCD00001211; DSSTox_GSID_20328; CHEBI:3682; ZINC3860369; Danthron, BAN; BRD-K10065684-001-03-3; BSPBio_002259; danthrone; OR61434; NCGC00091367-04; CS-4392; LS-587; BG01537787; ZX-AS004388; SR-01000721864; s4561; NSC-7210; Dantrona [INN-Spanish]; FT-0624445; Dorbane; 1,8-Dihydroxyanthraquinone, 96%; KBio3_001479; Zwitsalax; CHEMBL53418; CTK3J0719; Tox21_111122; ARONIS23892; KSC490O1T; NSC7210; SPECTRUM211468; Scatron D; ACMC-20mzuc; SMR000059018; 140861-59-2; Spectrum5_000324; Dantrona; BG00609013; D07107; BDBM11316; AB00051961_09; Chrysazine; NSC38626; Spectrum3_000650; Pastomin; Dantrone [INN-French]; Dorbanex (Salt/Mix); KBio1_000284; MLS000069608; BRD-K10065684-001-02-5; CHRYSAZIN, PRACT; Dantronum; NSC-755828; 1,8-Dihydroxyanthrachinon; 1,8-dihydroxy-9,10-dihydroanthracene-9,10-dione; Tox21_200986; Anthraquinone-related compound; Pilules Vinchy N.F. (TN); component of Doxidan; IDI1_000284; D0563; DSSTox_RID_75516; QBPFLULOKWLNNW-UHFFFAOYSA-N; Anthraquinone,8-dihydroxy-; Laxipurin; MCULE-5800615690; 1,8-Dihydroxyanthracene-9,10-dione (Danthron); A803710; Antrapurol; DivK1c_000284; HS-1003; Diaquone; Bancon; CTK0F1106; HY-B0923; AN-43229; 1,8-dihydroxy-anthraquinone; Dorbantyl; 1,8-Dihydroxyanthra-9,10-quinone; Dorbantyl (Salt/Mix); Neokutin S; Dantronum [INN-Latin]; AK208660; NCIMech_000114; TR-003068; Pharmakon1600-00211468; Spectrum2_000603; 343235-40-5; NCGC00091367-07; SCHEMBL83688; Istizin; SPBio_000506; component of Doxan; NSC-38626; 1,8 Dihydroxy Anthraquinone; 32073-07-7; Dantron (INN); W-108572; KBio2_004798; NCGC00091367-03; component of Dorbantyl; 1,8-Dihydroanthraquinone; R229; Dantrone; NINDS_000284; AKOS001583216; WLN: L C666 BV IVJ DQ NQ; 1,4,5,8-Tetroxyantraquinone; BB_NC-0487; C14H8O4; Tox21_111122_1; RP28420; Prugol; Istizine; BBC/171; 1,10-Anthracenedione, 8,9-dihydroxy- C14H8O4 240.21 g/mol C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O
TCMBANKIN059438 2-methoxy-4-propenyl phenol C10H12O2 164.2 g/mol CC=CC1=CC(=C(C=C1)O)OC
TCMBANKIN060497 dioscin C45H72O16 869.04 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1
TCMBANKIN060725 vincaleukoblastine;vinblastine;leurosidine;vincovalinine C46H58N4O9 810.97 g/mol CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
TCMBANKIN061091 stearic acid CH3(CH2)16COOH 284.5 g/mol CCCCCCCCCCCCCCCCCC(=O)O
TCMBANKIN061570 curcumin (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; Curcumin; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; Kacha haldi; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; ZINC00899824; 458-37-7; SDCCGMLS-0066836.P001; SCHEMBL2622435; Spectrum3_001990; DivK1c_006683; KBio1_001627; SpecPlus_000587; SPBio_001728; Spectrum2_001714; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one; NSC32982; Turmeric oleoresin (79%-85% curcumin); Yellow Root; Halad; Diferaloylmethane; kachs haldi; safra d'inde; Curcumin, 95% (total curcuminoid content), from Turmeric rhizome; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; GTPL7000; Turmeric, oleoresin; CI 75300; MFCD00008365; curcuma longa l. root oil hydrodistilled; DSSTox_CID_1421; NSC-687842; C21H20O6; Merita earth; NCGC00017159-11; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; NCGC00017159-06; I06-2497; BDBM50140172; I14-19358; MLS001148449; LS-125; NCGC00023332-04; SCHEMBL8441; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; BIDD:ER0479; 458-37-7; Turmeric root oil; Tox21_111505; BDBM50067040; 1790-EP2308861A1; Safran d'Inde; Turmeric oil (Curcuma longa L.); NSC 687842; Tumeric yellow; NCGC00017159-05; Curcuma oil; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; EINECS 207-280-5; 15845-47-3; E 100; Curcuma longa l. oleoresin; Curcuma longa l. root oleoresin; SR-01000000149-2; NCGC00017159-10; D0H8LC; HMS3649K06; Turmeric oleoresin; Orange Root; Curcumin (Natural); Indian saffron; Curcumin, United States Pharmacopeia (USP) Reference Standard; NCGC00017159-07; CCG-36107; Curcumin solution, ~0.1 % (w/v) (in ethanol with 2M HCl (99:1 v/v)), for TLC derivatization; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcurmin; 1,5-Di(vanillyliden)acetylaceton; I06-0010; Natural yellow 3; SMR000058237; cid_969516; Zlut prirodni 3; CHEMBL140; CAS-458-37-7; Curcumin, analytical standard; BG0601; ZX-AT003872; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; BCP9000557; Yellow puccoon; Tumeric oleoresin; DB11672; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; BG00706978; NSC687842; AC1LJ6T6; SCHEMBL8440; SR-01000000149; Tox21_201116; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; J10108; C.I. Natural Yellow 3; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin (synthetic); BIC8500; NCGC00017159-09; CCRIS 5804; NCGC00023332-05; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; W-5038; 1,7-DI(4-HYDROXY-3-METHOXYPHENYL)HEPTA-1,6-DIENE-3; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; FEMA No. 3086; 1790-EP2305629A1; BB_NC-01422; BC678109; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; Yellow Ginger; Diferuloylmethane; BRN 2306965; Bio-0677; AC1Q46A0; 98% curcurmin); cid_5281767; ZINC899824; Oils, galangal; 33171-04-9; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; curcuma longa l. root oil CO2 extract; Gelbwurz; OR24598; Oil of turmeric; Curcuma oil (Curcuma longa); MLS000069631; 1,5-Divanillyliden-2,4-pentandion; BDBM29532; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; UNII-IT942ZTH98; Yellow, Turmeric; BCP0726000035; Tox21_110803; KB-251224; CU-01000001305-2; Turmeric oil; HMS2233K04; D07SDQ; ST055629; Curcumin, primary pharmaceutical reference standard; CCG-36020; BRD-K07572174-001-19-6; MolPort-001-763-682; DSSTox_GSID_31077; DSSTox_RID_78861; Turmeric; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; NSC-32982; Kacha haldi; HY-N0005; Kurkumin [Czech]; Haldar; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; Turmeric (>98% curcurmin); GP8291; M212; Zlut prirodni 3 [Czech]; VFLDPWHFBUODDF-FCXRPNKRSA-N; LS-2189; Turmeric yellow; Turmeric extract (Curcuma longa L.); Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; TR-032605; Curcuma longa l. root oil; FEMA No. 3085; curouma; Tu rmeric root oil; Opera_ID_1627; AC-24238; 73729-23-4; Halud; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; RTR-032605; Yo-Kin; NCGC00023332-03; trans,trans-Curcumin; Curcuma longa l. oil; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; IT942ZTH98; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; diferuloylmethan; cMAP_000052; N1839; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; BG01656528; Curcuma; CCRIS 3257; Diferulylmethane; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); NCGC00017159-04; SC-17381; BRD-K07572174-001-22-0; turmeric root oil hydrodistilled; Oils, curcuma; 458C377; Hydrastis; AK316302; Haldar, Souchet; Natural Yellow3; 4-08-00-03697 (Beilstein Handbook Reference); E 100 (Dye); 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; CS-1490; Indian turmeric; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); Kurkumin; Curcumin I; Souchet; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; HSDB 4334; Haidr; NCI-C61325; BBL027711; Golden seal; SCHEMBL13521974; CC0179; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; Terra Merita; NCGC00258668-01; SBB006495; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); STL371943; AN-23454; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 8024-37-1; Curcuma longa oils; 91884-86-5; AKOS001305497; BRD-K07572174-001-02-2; Turmeric extract; TURMERIC, OLEORESIN (CURCUMIN) (SEE ALSO CURCURMIN (458-37-7)); CI Natural Yellow 3; Cucurmin; CHEBI:3962; DTXSID8031077; DB-002681; Curcumine; Turmeric root oleoresin; curcumin; turmeric root oil CO2 extract; Curcumin, from Curcuma longa (Turmeric), powder; NCGC00017159-12; 79257-48-0; C.I. 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; NSC 32982; SR-01000000149-5, curcumine;curcumin IC21H20O6 368.4 g/mol COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O
TCMBANKIN061617 eugenol 4-Allyl-2-methoxyphenol C10H12O2 COC1=C(C=CC(=C1)CC=C)O
TCMBANKIN061666 oroxylin 5,7-dihydroxy-6-methoxy-2-phenyl-4H-chromen-4-one; CTK1D7949; ZINC5998558; Oroxylin A; CHEMBL183513; 5,7-Dihydroxy-6-methoxy-2-phenyl-chromen-4-one; SC-69298; NP-005013; HY-N0560; MolPort-019-937-219; 5,7-dihydroxy-6-methoxy-2-phenyl-4H-1-benzopyran-4-one; AKOS015903364; Oroxylin-A; MFCD02259441; UNII-53K24Z586G; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one; 6-Methoxybaicalein;; FT-0688332; Oroxylin A, >=98% (HPLC); CHEBI:61668; 5,7-dihydroxy-6-methoxyflavone; BDBM50430091; AC1NSZBG; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl-; 5,7-Dihydroxy-6-methoxyflavone;; Y0150; I14-19006; baicalein 6-methyl ether; 53K24Z586G; DTXSID70197375; Baicalein 6-methyl ether;6-Methoxybaicalein; 480-11-5; SCHEMBL431423; LMPK12111096; Oroxylin; CS-4948 C16H12O5 284.26 g/mol COC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC=CC=C3)O
TCMBANKIN061952 Crude fiber SiO2 O=[Si]=O

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000009 Neoplasms Abnormality of the nervous system; Neoplasm Neoplastic Process disease
TCMBANKDI000018 Digestive System Diseases; Neoplasms; Endocrine System Diseases Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI000023 Skin and Connective Tissue Diseases; Immune System Diseases Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000061 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process group
TCMBANKDI000068 Neoplasms; Stomatognathic Diseases Neoplasm; Abnormality of head or neck Neoplastic Process group
TCMBANKDI000071 Digestive System Diseases; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI000076 Neoplasms - Neoplastic Process group
TCMBANKDI000078 Neoplasms; Skin and Connective Tissue Diseases Abnormality of the integument; Neoplasm Neoplastic Process group
TCMBANKDI000088 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process group
TCMBANKDI000092 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI000296 Eye Diseases Abnormality of the immune system; Abnormality of the eye Disease or Syndrome disease
TCMBANKDI000368 Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI001068 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI001279 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI001299 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Cardiovascular Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI001795 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Injury or Poisoning disease
TCMBANKDI002512 Digestive System Diseases Abnormality of the digestive system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI002624 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI002974 Neoplasms - Neoplastic Process disease
TCMBANKDI003071 Wounds and Injuries - Disease or Syndrome disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI003411 - - Disease or Syndrome disease
TCMBANKDI004086 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI004145 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction group
TCMBANKDI004222 Eye Diseases Abnormality of the eye Disease or Syndrome disease
TCMBANKDI004331 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Disease or Syndrome phenotype
TCMBANKDI004344 Nervous System Diseases; Endocrine System Diseases - Disease or Syndrome group
TCMBANKDI004576 Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI004922 Nutritional and Metabolic Diseases; Nervous System Diseases; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI005272 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Sign or Symptom phenotype
TCMBANKDI005318 Digestive System Diseases; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI006127 Nervous System Diseases; Mental Disorders - Disease or Syndrome disease
TCMBANKDI006450 Stomatognathic Diseases - Disease or Syndrome disease
TCMBANKDI006489 - Abnormality of the skeletal system; Abnormality of the cardiovascular system Pathologic Function phenotype
TCMBANKDI006660 Neoplasms; Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI006819 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases - Disease or Syndrome disease
TCMBANKDI007012 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Pathologic Function phenotype
TCMBANKDI007038 Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Eye Diseases; Musculoskeletal Diseases; Nervous System Diseases Abnormality of the eye Disease or Syndrome disease
TCMBANKDI007135 - - Disease or Syndrome disease
TCMBANKDI007362 Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI007520 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI007539 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases Abnormality of the nervous system Congenital Abnormality disease
TCMBANKDI007765 Digestive System Diseases - Disease or Syndrome disease
TCMBANKDI007782 Neoplasms - Neoplastic Process disease
TCMBANKDI007957 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Otorhinolaryngologic Diseases Abnormality of the ear Disease or Syndrome disease
TCMBANKDI008751 Pathological Conditions, Signs and Symptoms - Sign or Symptom phenotype
TCMBANKDI009099 Nutritional and Metabolic Diseases; Endocrine System Diseases - Experimental Model of Disease disease
TCMBANKDI009231 Pathological Conditions, Signs and Symptoms; Infections Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI009278 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI009680 Respiratory Tract Diseases; Immune System Diseases Abnormality of the respiratory system Disease or Syndrome group
TCMBANKDI009702 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome phenotype
TCMBANKDI009722 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Pathologic Function phenotype
TCMBANKDI009821 Pathological Conditions, Signs and Symptoms - Finding phenotype
TCMBANKDI009911 Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Eye Diseases; Musculoskeletal Diseases; Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI009912 Pathological Conditions, Signs and Symptoms Abnormality of metabolism/homeostasis Sign or Symptom phenotype
TCMBANKDI010048 Infections; Respiratory Tract Diseases Abnormality of the immune system; Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI010160 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome group
TCMBANKDI010346 Digestive System Diseases Abnormality of the digestive system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI010507 - - Sign or Symptom phenotype
TCMBANKDI011032 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI011173 Neoplasms - Neoplastic Process disease
TCMBANKDI011315 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI011393 Digestive System Diseases - Disease or Syndrome disease
TCMBANKDI011458 Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI011480 Cardiovascular Diseases Abnormality of the cardiovascular system Congenital Abnormality disease
TCMBANKDI011608 Neoplasms; Nervous System Diseases - Neoplastic Process disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI012119 Pathological Conditions, Signs and Symptoms Abnormality of the nervous system Cell or Molecular Dysfunction phenotype
TCMBANKDI012157 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome group
TCMBANKDI012321 - Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI012424 Pathological Conditions, Signs and Symptoms; Neoplasms - Pathologic Function phenotype
TCMBANKDI012506 Neoplasms - Neoplastic Process disease
TCMBANKDI012922 Neoplasms; Stomatognathic Diseases Neoplasm; Abnormality of head or neck Neoplastic Process group
TCMBANKDI012932 Infections; Immune System Diseases - Disease or Syndrome group
TCMBANKDI012976 Neoplasms; Stomatognathic Diseases - Neoplastic Process disease
TCMBANKDI013495 Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI013531 Eye Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI013541 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI014088 Respiratory Tract Diseases; Cardiovascular Diseases Abnormality of the respiratory system; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI014132 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI014161 Stomatognathic Diseases Abnormality of the immune system; Abnormality of head or neck Disease or Syndrome group
TCMBANKDI014531 Pathological Conditions, Signs and Symptoms; Neoplasms; Musculoskeletal Diseases - Neoplastic Process disease
TCMBANKDI014817 - - Neoplastic Process disease
TCMBANKDI014941 Eye Diseases - Disease or Syndrome disease
TCMBANKDI015238 Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI015290 Nervous System Diseases; Cardiovascular Diseases Abnormality of the nervous system; Abnormality of the cardiovascular system Pathologic Function disease
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI015491 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases; Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI016050 Neoplasms; Skin and Connective Tissue Diseases - Neoplastic Process disease
TCMBANKDI016439 Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI016800 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI016890 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017483 Neoplasms - Neoplastic Process phenotype
TCMBANKDI017642 Neoplasms Abnormality of the integument; Neoplasm Neoplastic Process disease
TCMBANKDI017700 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI017746 Infections; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI018731 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018931 - - Finding phenotype
TCMBANKDI019362 - - Disease or Syndrome disease
TCMBANKDI019558 Infections Abnormality of the immune system Disease or Syndrome group
TCMBANKDI019927 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI020079 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI020257 Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI020284 Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI020421 Pathological Conditions, Signs and Symptoms - Sign or Symptom phenotype
TCMBANKDI020466 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI020794 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease
TCMBANKDI021622 Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI021888 Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI022361 Pathological Conditions, Signs and Symptoms; Eye Diseases - Sign or Symptom phenotype
TCMBANKDI022473 Neoplasms - Neoplastic Process disease
TCMBANKDI022682 Neoplasms; Female Urogenital Diseases and Pregnancy Complications - Neoplastic Process disease
TCMBANKDI023181 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI023437 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases - Disease or Syndrome disease
TCMBANKDI023464 Nervous System Diseases Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI023498 Skin and Connective Tissue Diseases; Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI024057 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Disease or Syndrome phenotype
TCMBANKDI024262 - - Neoplastic Process phenotype
TCMBANKDI024355 Otorhinolaryngologic Diseases - Disease or Syndrome disease
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI024875 Nutritional and Metabolic Diseases; Musculoskeletal Diseases - Disease or Syndrome disease
TCMBANKDI025299 Neoplasms - Neoplastic Process disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI025469 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases - Acquired Abnormality phenotype
TCMBANKDI026459 Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI026625 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome group
TCMBANKDI026823 Nutritional and Metabolic Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI027026 Neoplasms; Skin and Connective Tissue Diseases - Neoplastic Process disease
TCMBANKDI027089 Pathological Conditions, Signs and Symptoms - Disease or Syndrome disease
TCMBANKDI027354 Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases Abnormality of the genitourinary system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI027628 Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases - Disease or Syndrome disease
TCMBANKDI027942 - Abnormality of the eye Disease or Syndrome disease
TCMBANKDI028471 Respiratory Tract Diseases; Otorhinolaryngologic Diseases - Disease or Syndrome group
TCMBANKDI028799 Eye Diseases - Disease or Syndrome disease
TCMBANKDI029321 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI029556 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis; Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI029899 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process group
TCMBANKDI030041 Hemic and Lymphatic Diseases - Neoplastic Process disease
TCMBANKDI030416 Infections - Disease or Syndrome disease
TCMBANKDI030540 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI030869 Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI031091 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Otorhinolaryngologic Diseases - Disease or Syndrome disease
TCMBANKDI031189 Neoplasms Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI031754 Pathological Conditions, Signs and Symptoms; Nervous System Diseases - Pathologic Function phenotype
TCMBANKDI032222 Nervous System Diseases; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI032413 Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI032496 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis Disease or Syndrome disease